The UK inhalable drug market is anticipated to grow at a CAGR of 2.0% over the forecast period (2020-2026). The key aspect that drives the growth of the market includes the rising prevalence of various respiratory and non- respiratory diseases and the increasing geriatric population. Besides, the inclination of the people towards the sedentary lifestyle along with unhealthy eating habits such as smoking accelerates the prevalence of several respiratory diseases such as COPD and asthma, which ultimately aids in the growth of the market. In addition, increasing R&D and investments by big pharmaceutical companies in life science research along with innovations are likely to propel the growth of the market in the country.
Browse the full report description UK Inhalable Drugs Market Size, Share & Trends Analysis Report by Application (Respiratory Diseases and Non-Respiratory Diseases), By Route of Administration (Nasal and Mouth), and Forecast 2020-2026 at https://www.omrglobal.com/industry-reports/uk-inhalable-drugs-market
Further, recent developments by the companies in the country are also encouraging market growth. Some of the key players operating in the industry include F. Hoffmann-La Roche Ltd., Novartis AG, AstraZeneca Plc, and others. The outbreak of COVID-19 has encouraged the manufacturers to develop novel drugs, including inhalable drugs. For instance, in July 2020, Synairgen Plc, a UK-based drug development company developed an inhaled formulation of interferon beta that aided in reducing the risk of developing severe diseases in COVID-19 patients. Thus, such launches and innovations by the players in the country are likely to encourage market growth.
Market Coverage
Key questions addressed by the report
o Recovery Timeline
o Deviation from the pre-COVID-19 forecast
o Most affected segment
UK Inhalable Drugs Market – Segmentation
By Application
By Route of Administration
To learn more about this report request a free sample copy
@ https://www.omrglobal.com/request-sample/uk-inhalable-drugs-market